Hologic (NASDAQ:HOLX) traded higher in the last at $34.15, gaining 0.01 points or 0.03%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-2.43) million. The composite uptick value of $2.65 million was eclipsed by the accrued downtick value of $5.07 million, thereby ensuring the up/down ratio of 0.52. For the week, the shares have posted returns of 1.01%.A block trade registered during the day has revealed $0 million in upticks and $2.57 million in downticks. The up/down ratio in this case turned out to be 0. The net money flow for the block trade was $(-2.57) million.
The stock has recorded a 20-day Moving Average of 0.38% and the 50-Day Moving Average is 2.22%. The company shares have dropped 9.99% in the past 52 Weeks. On August 18, 2015 The shares registered one year high of $43 and one year low was seen on February 12, 2016 at $31.84. The 50-day moving average is $33.92 and the 200 day moving average is recorded at $35.34. S&P 500 has rallied 1.93% during the last 52-weeks.
Hologic (NASDAQ:HOLX): The stock opened at $34.23 on Tuesday but the bulls could not build on the opening and the stock topped out at $34.40 for the day. The stock traded down to $33.87 during the day, due to lack of any buying support eventually closed down at $33.88 with a loss of -0.76% for the day. The stock had closed at $34.14 on the previous day. The total traded volume was 2,208,209 shares.
Currently the company Insiders own 0.84% of Hologic shares according to the proxy statements. Institutional Investors own 91.97% of Hologic shares. On the companys insider trading activities,The director of Hologic Inc, Levy Lawrence M sold 17,794 shares at $34.41 on June 1, 2016. The Insider selling transaction had a total value worth of $612,292. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.